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IBMTR/ABMTR Mortimer M. Bortin Awards 
for Best Clinical Research Abstracts
Mortimer M. Bortin, M.D., was one of the founding members of the International Bone Marrow Transplant Registry and
served as its Scientific Director for more than 30 years. The Mortimer M. Bortin Award, established to commemorate Dr.
Bortin’s contribution to the field of transplantation, is presented each year to investigators submitting abstracts for
presentation at the annual IBMTR/ABMTR meeting. The abstracts must address important issues in blood and marrow
transplantation and be of outstanding scientific merit. This year three $1,000 awards will be presented on behalf of the
Mortimer B. Bortin Fund Awards Committee. The awards are supported by an educational grant from Gambro BCT, Inc.
1
ALLOGENEIC MESENCHYMAL STEM CELL INFUSION FOR TREATMENT
OF PATIENTS WITH METACHROMATIC LEUKODYSTROPHY (MLD)
AND HURLER (MPS-I)
Koç, O.N.1; Day, J.2; Raghavan, S.3; Kolodny, E.3; Lazarus, H.M.1;
Gerson, S.L.1; Caplan, A.I.1; Krivit, W.2 1. Case Western Reserve Uni-
versity, Cleveland, OH; 2. University of Minnesota, Minneapolis, MN;
3. New York university, New York, NY
Complete and sustained hematopoietic engraftment after allo-
BMT leads to correction of the pathophysiology in MLD and
MPS-I and allows for long term survival. However, there are
residual skeletal and neurologic defects that persist. We postulated
that some of these defects could be corrected by infusion of nor-
mal allo-Mesenchymal Stem Cells that are shown to express high
amounts of α-L-iduronidase and arylsulfatase-A, deficient in
MPS-I and MLD respectively. Ex vivo culture expansion of donor
MSCs resulted in 5-10,000 fold increase in their number com-
pared to what is found in un-manipulated BM. 2-10 x 106
MSCs/kg were infused into 11 patients (6 MLD and 5 MPS-I).
There was no toxicity related to infusion and no GVHD was
observed with a median follow up of 1 year. We have not detected
any recipient T-lymphocyte response to allo-MSCs. Culture-puri-
ﬁed MSCs were genotyped either by FISH or by PCR 2, 60 and ≥
180 days after MSC infusion. In the majority of patients MSCs
remained host type. In two patients T+60 days bone marrow
derived MSCs contained 0.4 and 2% donor cells by FISH with a
corresponding increase in enzyme activity. One of the 3 patients
with MPS-I had improved bone density (BD) along with a
decrease in N-teleopeptide excretion in urine. Three of 6 MLD
patients had improved BD and 4 of 6 had improved nerve conduc-
tion velocity (NCV). In contrast, historic data in this patient pop-
ulation show ongoing loss of NCV and BD despite allo-BMT,
making our ﬁndings signiﬁcant and exciting. In conclusion supple-
mental allogeneic MSC infusion is safe and can result in improve-
ment in disease parameters such as BD and NCV in patients with
MPS-I and MLD. These observations justify further evaluation of
MSCs in these disorders. We are currently testing multiple MSC
infusions in this setting.
2
UPDATED OUTCOME IN FULL-HAPLOTYPE MISMATCHED TRANS-
PLANTS FOR ACUTE LEUKEMIA
Martelli, M.F.1; Aversa, F.1; Tabilio, A.1; Velardi, A.1; Reisner, Y.2
1. University of Perugia, Perugia, Italy; 2. Weizmann Institute,
Rehovot, Israel
A megadose of T-depleted HSC is crucial in promoting engraft-
ment across the HLA barriers in acute leukemia patients (Aversa
et al. Blood 1994; 84: 3948. NEJM 1998;339:1186), Modiﬁcations
to the transplant protocol since October 1995 include ﬂudarabine
instead of cyclophosphamide in the TBI-based conditioning regi-
men; T cell depletion of PBPCs by selection of CD34+ cells using
the Ceprate (43 patients) or, more recently, the CliniMacs (44
patients) devices. 87 acute leukemia patients (46 AML, 41 ALL),
median age 26 years (range 4-62) have been transplanted. 14 were
in bad-risk CR I, 26 in CR II, 9 in CR III and 40 (44%) in relapse
at transplant. The graft contained a median of 12 x 106 CD34+
cells/kg and 1.5 x 104 CD3+ cells/kg. Primary full-donor engraft-
ment was achieved in 81 (93%); 5 engrafted after a second trans-
plant from different relatives. Without any post-transplant
immunosuppression, acute GvHD developed in only 3 cases. 35
non-leukemic deaths, mainly due to infections, occurred in these
very high risk patients. In vitro susceptibility of AML cells to
alloreactive NK lysis predicted a low probability of AML relapse
(0.25 ± 0.05) (Ruggeri et al. Blood 1999;94:333). Five-year proba-
bility of EFS is 0.33 and 0.18 for AML and ALL, respectively. In
the last 44 patients who did not receive post-transplant G-CSF,
immunological reconstitution markedly improved (Volpi et al.,
Blood 2001;97:2514). 23 had been transplanted in CR. Their
TRM was 30%. At a median follow-up of 15 months (range 2-30),
62% of the 15 AML and 44% of the 8 ALL survive event-free.
These results indicate the mismatched transplant should be
offered to high-risk acute leukemia patients without a HLA-iden-
tical donor not as a last resort, but as a viable option in the early
stages of the disease. 
3
NON-MYELOABLATIVE REGIMEN PRESERVES “NICHES” ALLOWING
FOR PERIPHERAL EXPANSION OF DONOR T CELLS
Chao, N.J.; Liu, C.X.; Rooney, B. Duke University, Durham, NC
T-cell reconstitution following allogeneic stem cell transplantation
(SCT) involves thymic education of donor-derived precursors or
peripheral expansion of mature T-cells transferred in the graft. We
measured T cell recovery in adult cord blood recipients by pheno-
typic analyses, measurement of T cell receptor Vbeta families by
spectratyping and by T-cell receptor excision circles (sjTRECs)
which are generated within the thymus and identify new thymic emi-
grants and those that have not divided. Two groups of patients were
compared, those receiving a myeloablative regimen consisting of
fractionated TBI or busulfan with melphalan and anti-thymocyte vs.
those receiving a non-myeloablative regimen consisting of ﬂudara-
bine, cyclophosphamide and anti-thymocyte globulin. Both groups
of patients received cyclosporine and prednisone for graft-versus-
host disease prevention. Myeloid and to a lesser degree, lymphoid
recovery was markedly rapid in the non-ablative regimen recipients
of cord blood compared to ablated recipients by six months. The
median time to myeloid recovery was 24 days in ablated patients
compared to 10 days in the non-myeloablated patients. Moreover,
spectratyping revealed robust and full recovery in every Vbeta family
in the non-myeloablative regimen recipients. In contrast, the fully
ablated patients had very few Vbeta families represented and within
the families that were present, they were monoclonal or oligoclonal.
Of note, all the patients receiving the non-myeloablative regimen
were 100% donor by microsattelitte polymorphism within 6 months,
suggesting that the T cell repertoire was donor and not residual
recipient cells. sjTRECs were not detected in either population of
patients. We conclude that early T-cell recovery after UCB trans-
plant occurs primarily through peripheral expansion of adoptively
transferred donor T-cells. The non-myeloablated patients have pre-
served niches where the donor T cells can expand which are likely
damaged in the recipients of the ablative regimen resulting in skew-
ing of the T-cell repertoire.
